- Home
- GSIW vs INTS Comparison
GSIW vs INTS Comparison
Compare GSIW & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSIW
- INTS
- Stock Information
- Founded
- GSIW 2016
- INTS 2012
- Country
- GSIW Hong Kong
- INTS United States
- Employees
- GSIW N/A
- INTS N/A
- Industry
- GSIW
- INTS Biotechnology: Pharmaceutical Preparations
- Sector
- GSIW
- INTS Health Care
- Exchange
- GSIW Nasdaq
- INTS Nasdaq
- Market Cap
- GSIW 8.3M
- INTS 8.7M
- IPO Year
- GSIW 2023
- INTS 2023
- Fundamental
- Price
- GSIW $1.15
- INTS $0.46
- Analyst Decision
- GSIW
- INTS Strong Buy
- Analyst Count
- GSIW 0
- INTS 3
- Target Price
- GSIW N/A
- INTS $8.50
- AVG Volume (30 Days)
- GSIW 2.1M
- INTS 1.3M
- Earning Date
- GSIW 12-31-2024
- INTS 05-13-2025
- Dividend Yield
- GSIW N/A
- INTS N/A
- EPS Growth
- GSIW N/A
- INTS N/A
- EPS
- GSIW N/A
- INTS N/A
- Revenue
- GSIW $1,313,795.00
- INTS N/A
- Revenue This Year
- GSIW N/A
- INTS N/A
- Revenue Next Year
- GSIW N/A
- INTS N/A
- P/E Ratio
- GSIW N/A
- INTS N/A
- Revenue Growth
- GSIW N/A
- INTS N/A
- 52 Week Low
- GSIW $0.35
- INTS $0.29
- 52 Week High
- GSIW $12.30
- INTS $5.10
- Technical
- Relative Strength Index (RSI)
- GSIW 78.55
- INTS 38.44
- Support Level
- GSIW $0.73
- INTS $0.29
- Resistance Level
- GSIW $0.77
- INTS $0.63
- Average True Range (ATR)
- GSIW 0.10
- INTS 0.09
- MACD
- GSIW 0.03
- INTS 0.06
- Stochastic Oscillator
- GSIW 86.84
- INTS 50.88
About GSIW Garden Stage Limited
Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: a) I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong, and b) I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.